{"entity":{"id":"nouscom","kind":"company","name":"Nouscom","aka":[],"tldr":"Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.","summary":"Nouscom, based in Basel and Rome, is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens, to intercept cancer in people with Lynch syndrome. A phase 1b/2 in Lynch carriers, published in Nature Medicine in March 2026, showed safety and immune responses in most participants, re-treatment and long-term follow-up data were selected for an ESMO 2026 oral, and the vaccine has also been tested with pembrolizumab in microsatellite-instability-high tumours. OnCo links it to colorectal cancer, to off-the-shelf cancer vaccines and chemoprevention, to the MSI-H and neoantigen terms, and to the idea of a randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers. Whether immune responses translate into fewer cancers in carriers is the question only a prevention trial can answer. The off-the-shelf vaccine page carries the field.","asOf":"2026-09-04","links":[{"label":"Nature Medicine 2026","url":"https://www.nature.com/articles/s41591-025-04182-9"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy","prevention"],"technologies":["shared-antigen-vaccine","chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["msi","neoantigen"],"trials":["nct04041310"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel / Rome","country":"CH","companyType":"biotech","website":"https://nouscom.com","investors":["andera-partners"],"funding":[]},"route":"/companies/nouscom/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"term":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/"}],"trial":[{"id":"nct04041310","kind":"trial","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","route":"/trials/nct04041310/"}],"company":[{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/"}],"idea":[{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/"}]}}